Comparative Pharmacology
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE versus ENLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE versus ENLON.
EDROPHONIUM CHLORIDE vs ENLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits acetylcholinesterase, prolonging acetylcholine action at neuromuscular junction and autonomic ganglia.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, inhibiting neuromuscular transmission.
10 mg IV bolus, may repeat up to total 10 mg. For myasthenia gravis diagnosis: 2 mg IV test dose, then 8 mg IV if no reaction after 45 seconds.
Intravenous: 0.1 mg/kg followed by 1-2 mg/min infusion for reversal of neuromuscular blockade; adjust based on twitch response.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours; in anephric patients, half-life may be prolonged up to 6-8 hours, requiring dose adjustment.
Terminal elimination half-life of 1.5-2.5 hours; prolonged in renal impairment and elderly patients
Primarily renal excretion as unchanged drug (approximately 70-80% within 4 hours); minor biliary/fecal elimination accounts for <10%.
Primarily renal excretion of unchanged drug (85-95%), with minor fecal elimination (<5%)
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor